IP Library › Granted Patent US 10,758,497
Granted Patent B2
US 10,758,497 · App. 16/594,317 · Granted Sep 1, 2020

Treatment of fragile x syndrome with cannabidiol

Inventors: Marcel Bonn-Miller (Lexington, NC); Nancy Tich (Chester, NJ); Donna Gutterman (Raleigh, NC); John Messenheimer (Moncure, NC); Terri Sebree (Gladwyne, PA)
Assignee: ZYNERBA PHARMACEUTICALS, INC.
A61K31/05A61K9/0014A61K9/06A61K36/185A61P25/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,758,497
App. No.
16/594,317
Granted
Sep 1, 2020
Kind
B2
Abstract

The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.

Claims (7)

1. A method of treating a human suffering from Fragile X Syndrome comprising: administering 250 mg or 500 mg of synthetic or purified cannabidiol in a pharmaceutically acceptable carrier to the human suffering from Fragile X Syndrome to effectively treat the Fragile X Syndrome in the human in need thereof.

2. The method of claim 1 , wherein the cannabidiol is (−)-cannabidiol.

3. The method of claim 1 , wherein the cannabidiol is formulated as a gel.

4. The method of claim 3 , wherein the cannabidiol is formulated as a permeation-enhanced gel.

5. The method of claim 1 , wherein the cannabidiol is administered in a single daily dose.

6. The method of claim 1 , wherein the cannabidiol is administered in two daily doses.

7. The method of claim 1 , wherein the cannabidiol is transdermally administered.

Assignments (2)
SUPPLEMENTAL CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 18, 2026
From: HARMONY BIOSCIENCES MANAGEMENT, INC. (F/K/A ZYNERBA PHARMACEUTICALS, INC.)
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 075642/0639 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2020
From: BONN-MILLER, MARCEL; TICH, NANCY; GUTTERMAN, DONNA; MESSENHEIMER, JOHN; SEBREE, TERRI
To: ZYNERBA PHARMACEUTICALS, INC.
Reel/Frame 051844/0293 →
Continuity (5)
Continuation 16249732 · Jan 16, 2019
Continuation 16144632 · Sep 27, 2018
Provisional Application 62632532 · Feb 20, 2018
Provisional Application 62564834 · Sep 28, 2017
Related Publication 20200030255A1 · Jan 30, 2020
Cited By (9)
US 12,186,280 US 12,186,282 US 12,213,951 US 12,226,373 US 12,268,699 US 12,409,131 US 12,409,132 US 12,582,664 US 12,714,718